1.4.3. Broad lines of the activities

Regulation (EU) No 1291/2013 of the European Parliament and of the Council of 11 December 2013 establishing Horizon 2020 - the Framework Programme for Research and Innovation (2014-2020) and repealing Decision No 1982/2006/EC Text with EEA relevance · European Union

Development of emerging technology areas such as synthetic biology, bioinformatics and systems biology, which hold great promise for innovative products and technologies and completely novel applications. Developing industrial biotechnology and industrial scale bio-process design for competitive industrial products and sustainable processes (e.g. chemical, health, mining, energy, pulp and paper, fibre-based products and wood, textile, starch, food processing) and its environmental and health dimensions, including clean-up operations. Development of platform technologies (e.g. genomics, meta-genomics, proteomics, metabolomics, molecular tools, expression systems, phenotyping platforms and cell-based platforms) to enhance leadership and competitive advantage in a wide number of sectors that have economic impacts.

← anx_I__cpt_21__cpt_1__cpt_8__cpt_2__text_3 · All articles · (a) Boosting cutting-edge biotechnologies as a future innovation driver →

Source: EUR-Lex (Cellar) · retrieved 2026-11-03 · Text as adopted (Official Journal); later amendments are not incorporated in this text.